• 1. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles Benzothiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles

Recent Advances in the Application of 2-Bromo-5-methyl-1,3-benzothiazole (CAS: 1093107-11-9) in Chemical Biology and Pharmaceutical Research

2-Bromo-5-methyl-1,3-benzothiazole (CAS: 1093107-11-9) has emerged as a key structural motif in recent chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its brominated benzothiazole core, has garnered significant attention due to its versatile reactivity and potential therapeutic applications. Recent studies have explored its role as a building block in the synthesis of novel bioactive molecules, particularly in the development of kinase inhibitors and antimicrobial agents.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-bromo-5-methyl-1,3-benzothiazole as a precursor in the synthesis of potent EGFR tyrosine kinase inhibitors. The bromine atom at the 2-position was found to be crucial for subsequent palladium-catalyzed cross-coupling reactions, enabling efficient diversification of the benzothiazole scaffold. Researchers reported that derivatives synthesized from this intermediate showed promising antiproliferative activity against non-small cell lung cancer cell lines, with IC50 values in the low micromolar range.

In antimicrobial research, a recent publication in Bioorganic & Medicinal Chemistry Letters highlighted the compound's potential in addressing antibiotic resistance. The electron-withdrawing bromo substituent was shown to enhance the reactivity of the benzothiazole ring towards nucleophilic aromatic substitution, facilitating the creation of novel quorum-sensing inhibitors. These derivatives demonstrated significant inhibition of biofilm formation in Pseudomonas aeruginosa at concentrations as low as 8 μg/mL, suggesting potential applications in combating persistent bacterial infections.

From a synthetic chemistry perspective, advances in continuous flow chemistry have improved the scalability of 2-bromo-5-methyl-1,3-benzothiazole production. A 2024 study in Organic Process Research & Development reported a novel continuous bromination protocol that achieved 92% yield with excellent regioselectivity, addressing previous challenges in large-scale synthesis. This development is particularly relevant for pharmaceutical applications where consistent quality and scalability are paramount.

The compound's unique electronic properties have also enabled its use in materials science applications. Recent work published in ACS Applied Materials & Interfaces described its incorporation into organic semiconductors for biosensing applications. The methyl group at the 5-position was found to improve solubility while maintaining favorable π-stacking interactions, making these materials suitable for flexible electronic devices in medical diagnostics.

Looking forward, the versatility of 2-bromo-5-methyl-1,3-benzothiazole positions it as a valuable scaffold for drug discovery programs targeting various disease areas. Current research efforts are focusing on expanding its application in PROTAC (proteolysis targeting chimera) development and covalent inhibitor design, leveraging the reactivity of the bromo substituent for targeted protein degradation strategies. These emerging applications underscore the compound's continued relevance in cutting-edge pharmaceutical research.

• 408328-13-2(2,6-Dibromobenzothiazole)
• 412923-48-9(2-Bromo-4,6-dimethylbenzothiazole, 97%)
• 73443-76-2(2-Bromo-4-methylbenzodthiazole)
• 2516-40-7(2-Bromo-1,3-benzothiazole)
• 1019111-64-8(2,5-Dibromo-benzothiazole)
• 1188053-04-4(2-Bromo-4,5-dimethylbenzothiazole)
• 898748-39-5(2-Bromo-6-tert-butyl-benzothiazole)
• 1019115-44-6(2-BROMO-4,7-DIMETHYLBENZOTHIAZOLE)
• 864265-77-0(2-Bromobenzodthiazole-6-carbonitrile)
• 3622-19-3(2-Bromo-6-methylbenzodthiazole)